| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| RNA, Small Interfering | 71 | 2025 | 898 | 17.990 |
Why?
|
| RNA Interference | 30 | 2025 | 618 | 6.060 |
Why?
|
| Huntington Disease | 10 | 2024 | 152 | 4.300 |
Why?
|
| Huntingtin Protein | 13 | 2024 | 141 | 4.180 |
Why?
|
| Oligonucleotides | 14 | 2025 | 219 | 3.830 |
Why?
|
| Lipids | 8 | 2022 | 316 | 3.310 |
Why?
|
| Gene Silencing | 22 | 2025 | 392 | 2.630 |
Why?
|
| Oligonucleotides, Antisense | 11 | 2024 | 142 | 2.580 |
Why?
|
| Nucleic Acids | 4 | 2024 | 60 | 2.360 |
Why?
|
| RNA, Messenger | 19 | 2025 | 1528 | 2.310 |
Why?
|
| Central Nervous System | 3 | 2024 | 197 | 2.090 |
Why?
|
| Mice | 42 | 2025 | 10802 | 2.030 |
Why?
|
| Animals | 62 | 2025 | 20576 | 2.030 |
Why?
|
| Superoxide Dismutase-1 | 2 | 2025 | 144 | 1.760 |
Why?
|
| Drug Delivery Systems | 6 | 2024 | 325 | 1.690 |
Why?
|
| Extracellular Vesicles | 3 | 2018 | 44 | 1.680 |
Why?
|
| Cholesterol | 6 | 2022 | 259 | 1.600 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 12 | 2020 | 260 | 1.470 |
Why?
|
| Neurons | 6 | 2019 | 909 | 1.360 |
Why?
|
| Fatty Acids | 3 | 2020 | 200 | 1.350 |
Why?
|
| Gene Transfer Techniques | 3 | 2020 | 314 | 1.210 |
Why?
|
| Trinucleotide Repeat Expansion | 3 | 2024 | 32 | 1.190 |
Why?
|
| RNAi Therapeutics | 3 | 2021 | 11 | 1.130 |
Why?
|
| Humans | 72 | 2025 | 62651 | 1.090 |
Why?
|
| HeLa Cells | 14 | 2019 | 532 | 1.080 |
Why?
|
| Tissue Distribution | 8 | 2024 | 293 | 1.070 |
Why?
|
| Exosomes | 2 | 2018 | 47 | 1.060 |
Why?
|
| RNA | 9 | 2024 | 422 | 1.060 |
Why?
|
| Organophosphorus Compounds | 3 | 2023 | 31 | 1.010 |
Why?
|
| Gene Expression Regulation | 7 | 2019 | 1611 | 0.980 |
Why?
|
| Ribose | 1 | 2025 | 5 | 0.970 |
Why?
|
| Drug Design | 3 | 2024 | 136 | 0.970 |
Why?
|
| Species Specificity | 1 | 2024 | 334 | 0.860 |
Why?
|
| Apolipoproteins E | 4 | 2024 | 109 | 0.860 |
Why?
|
| MutS Homolog 3 Protein | 1 | 2023 | 4 | 0.840 |
Why?
|
| Alzheimer Disease | 3 | 2024 | 718 | 0.800 |
Why?
|
| Liver | 12 | 2024 | 843 | 0.800 |
Why?
|
| Cell Nucleus | 2 | 2024 | 623 | 0.800 |
Why?
|
| RNA, Double-Stranded | 5 | 2023 | 111 | 0.780 |
Why?
|
| High-Throughput Screening Assays | 3 | 2017 | 78 | 0.770 |
Why?
|
| Chemokine CXCL10 | 1 | 2022 | 58 | 0.760 |
Why?
|
| Muscular Atrophy, Spinal | 1 | 2022 | 20 | 0.760 |
Why?
|
| Organophosphonates | 2 | 2021 | 22 | 0.750 |
Why?
|
| DNA | 2 | 2023 | 839 | 0.720 |
Why?
|
| Genetic Therapy | 6 | 2023 | 770 | 0.720 |
Why?
|
| Cells, Cultured | 9 | 2018 | 2154 | 0.720 |
Why?
|
| Skin Diseases | 1 | 2022 | 83 | 0.710 |
Why?
|
| Myostatin | 1 | 2020 | 14 | 0.710 |
Why?
|
| Phosphorothioate Oligonucleotides | 1 | 2020 | 10 | 0.700 |
Why?
|
| RNA Processing, Post-Transcriptional | 2 | 2018 | 102 | 0.690 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2025 | 507 | 0.650 |
Why?
|
| Brain Neoplasms | 2 | 2024 | 308 | 0.640 |
Why?
|
| Kidney | 5 | 2019 | 444 | 0.620 |
Why?
|
| Nanoparticles | 2 | 2022 | 517 | 0.620 |
Why?
|
| Disease Models, Animal | 9 | 2025 | 2173 | 0.600 |
Why?
|
| Blood-Brain Barrier | 1 | 2018 | 85 | 0.570 |
Why?
|
| Phosphorylcholine | 4 | 2019 | 44 | 0.570 |
Why?
|
| Vinyl Compounds | 1 | 2017 | 5 | 0.560 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2017 | 102 | 0.560 |
Why?
|
| Nervous System Diseases | 1 | 2019 | 106 | 0.560 |
Why?
|
| Parenchymal Tissue | 1 | 2017 | 5 | 0.550 |
Why?
|
| Base Pair Mismatch | 3 | 2024 | 36 | 0.530 |
Why?
|
| Anticholesteremic Agents | 1 | 2017 | 35 | 0.530 |
Why?
|
| Epidermal Growth Factor | 1 | 2016 | 47 | 0.530 |
Why?
|
| Nucleic Acid Conformation | 9 | 2017 | 242 | 0.530 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 283 | 0.510 |
Why?
|
| Acetylgalactosamine | 3 | 2024 | 10 | 0.510 |
Why?
|
| Drug Discovery | 1 | 2017 | 94 | 0.500 |
Why?
|
| Brain | 3 | 2024 | 1549 | 0.500 |
Why?
|
| Guanabenz | 1 | 2015 | 3 | 0.500 |
Why?
|
| Vesicular Transport Proteins | 1 | 2016 | 109 | 0.500 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2024 | 189 | 0.490 |
Why?
|
| Endosomes | 1 | 2016 | 178 | 0.480 |
Why?
|
| Mice, Inbred C57BL | 8 | 2024 | 3387 | 0.480 |
Why?
|
| Gene Knockdown Techniques | 1 | 2015 | 201 | 0.470 |
Why?
|
| Prodrugs | 1 | 2014 | 36 | 0.450 |
Why?
|
| Transfection | 9 | 2008 | 691 | 0.450 |
Why?
|
| RNA, Catalytic | 5 | 2005 | 21 | 0.440 |
Why?
|
| Base Sequence | 13 | 2018 | 1333 | 0.430 |
Why?
|
| Docosahexaenoic Acids | 3 | 2018 | 31 | 0.430 |
Why?
|
| MicroRNAs | 6 | 2024 | 675 | 0.420 |
Why?
|
| Mice, Transgenic | 4 | 2025 | 1271 | 0.420 |
Why?
|
| Mutation | 6 | 2024 | 2573 | 0.410 |
Why?
|
| 3' Untranslated Regions | 3 | 2012 | 92 | 0.410 |
Why?
|
| Sheep | 2 | 2024 | 179 | 0.400 |
Why?
|
| Gene Editing | 3 | 2024 | 309 | 0.400 |
Why?
|
| Cell Line | 10 | 2024 | 2038 | 0.400 |
Why?
|
| Corpus Striatum | 3 | 2023 | 96 | 0.390 |
Why?
|
| Lung | 3 | 2023 | 939 | 0.390 |
Why?
|
| Response Elements | 1 | 2012 | 44 | 0.380 |
Why?
|
| Biological Transport | 3 | 2018 | 292 | 0.380 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 2 | 2024 | 83 | 0.370 |
Why?
|
| RNA Stability | 3 | 2025 | 102 | 0.370 |
Why?
|
| RNA-Induced Silencing Complex | 4 | 2017 | 67 | 0.360 |
Why?
|
| Gene Regulatory Networks | 2 | 2012 | 157 | 0.360 |
Why?
|
| Molecular Targeted Therapy | 3 | 2018 | 129 | 0.360 |
Why?
|
| Reperfusion Injury | 2 | 2022 | 53 | 0.340 |
Why?
|
| Endocytosis | 3 | 2019 | 152 | 0.320 |
Why?
|
| Female | 11 | 2021 | 32478 | 0.320 |
Why?
|
| Rats | 3 | 2024 | 1977 | 0.320 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2008 | 297 | 0.310 |
Why?
|
| Base Pairing | 2 | 2006 | 45 | 0.300 |
Why?
|
| Gene Expression Profiling | 4 | 2008 | 761 | 0.300 |
Why?
|
| Liver Transplantation | 2 | 2022 | 215 | 0.290 |
Why?
|
| Hepatocytes | 3 | 2019 | 215 | 0.290 |
Why?
|
| Heart | 2 | 2020 | 282 | 0.280 |
Why?
|
| Genome, Human | 2 | 2021 | 234 | 0.280 |
Why?
|
| Neoplasms | 1 | 2018 | 1350 | 0.280 |
Why?
|
| Melanoma | 4 | 2021 | 331 | 0.280 |
Why?
|
| Genes, Reporter | 2 | 2025 | 256 | 0.280 |
Why?
|
| Structure-Activity Relationship | 3 | 2019 | 369 | 0.270 |
Why?
|
| Cell Culture Techniques | 2 | 2018 | 182 | 0.270 |
Why?
|
| Dystrophin | 2 | 2024 | 31 | 0.270 |
Why?
|
| Sequence Alignment | 2 | 2006 | 298 | 0.270 |
Why?
|
| Muscular Dystrophy, Duchenne | 2 | 2024 | 41 | 0.260 |
Why?
|
| RNA, Neoplasm | 1 | 2006 | 34 | 0.260 |
Why?
|
| Cell Line, Tumor | 8 | 2024 | 1451 | 0.250 |
Why?
|
| Gene Targeting | 2 | 2005 | 78 | 0.240 |
Why?
|
| Interferons | 1 | 2006 | 74 | 0.240 |
Why?
|
| Aspartic Acid Endopeptidases | 1 | 2025 | 37 | 0.240 |
Why?
|
| alpha-Synuclein | 1 | 2025 | 35 | 0.240 |
Why?
|
| Amyloid beta-Peptides | 2 | 2024 | 297 | 0.240 |
Why?
|
| Thionucleotides | 4 | 2005 | 38 | 0.240 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2025 | 77 | 0.230 |
Why?
|
| Exons | 2 | 2023 | 197 | 0.230 |
Why?
|
| Endoribonucleases | 1 | 2005 | 55 | 0.230 |
Why?
|
| Diphosphates | 3 | 1993 | 11 | 0.230 |
Why?
|
| Antagomirs | 1 | 2024 | 6 | 0.230 |
Why?
|
| RNA Helicases | 1 | 2005 | 92 | 0.230 |
Why?
|
| Tumor Cells, Cultured | 4 | 2018 | 454 | 0.220 |
Why?
|
| Trinucleotide Repeats | 1 | 2024 | 17 | 0.220 |
Why?
|
| Amyloidogenic Proteins | 1 | 2024 | 13 | 0.220 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2024 | 75 | 0.220 |
Why?
|
| tau Proteins | 1 | 2025 | 201 | 0.220 |
Why?
|
| Codon, Nonsense | 1 | 2024 | 58 | 0.220 |
Why?
|
| Apolipoprotein E4 | 1 | 2024 | 46 | 0.220 |
Why?
|
| Motor Neurons | 1 | 2025 | 212 | 0.210 |
Why?
|
| Genomics | 1 | 2007 | 357 | 0.210 |
Why?
|
| Janus Kinase Inhibitors | 1 | 2023 | 17 | 0.210 |
Why?
|
| Superoxide Dismutase | 1 | 2025 | 227 | 0.210 |
Why?
|
| Alleles | 2 | 2022 | 445 | 0.210 |
Why?
|
| Genetic Engineering | 2 | 2004 | 115 | 0.210 |
Why?
|
| Amyloid | 1 | 2024 | 68 | 0.210 |
Why?
|
| Neostriatum | 1 | 2023 | 25 | 0.210 |
Why?
|
| Phenylalanine-tRNA Ligase | 2 | 1993 | 2 | 0.210 |
Why?
|
| RNA, Transfer, Phe | 2 | 1993 | 3 | 0.210 |
Why?
|
| Dogs | 1 | 2024 | 324 | 0.210 |
Why?
|
| Organ Preservation | 2 | 2022 | 19 | 0.200 |
Why?
|
| Gene Expression | 2 | 2016 | 836 | 0.200 |
Why?
|
| Perfusion | 2 | 2022 | 73 | 0.200 |
Why?
|
| Lysine-tRNA Ligase | 2 | 1992 | 3 | 0.200 |
Why?
|
| Sequence Analysis, RNA | 1 | 2004 | 171 | 0.200 |
Why?
|
| Databases, Factual | 1 | 2006 | 852 | 0.200 |
Why?
|
| Molecular Sequence Data | 6 | 2008 | 1992 | 0.200 |
Why?
|
| Glioblastoma | 1 | 2024 | 157 | 0.200 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2022 | 36 | 0.190 |
Why?
|
| Drug Administration Routes | 1 | 2021 | 21 | 0.190 |
Why?
|
| Liposomes | 1 | 2022 | 106 | 0.190 |
Why?
|
| Tissue and Organ Procurement | 1 | 2022 | 43 | 0.190 |
Why?
|
| Cyclophilins | 2 | 2016 | 12 | 0.190 |
Why?
|
| Bulbo-Spinal Atrophy, X-Linked | 1 | 2021 | 1 | 0.190 |
Why?
|
| Receptors, Androgen | 1 | 2021 | 31 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 4 | 2005 | 103 | 0.180 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2023 | 288 | 0.180 |
Why?
|
| Melanoma, Experimental | 1 | 2021 | 42 | 0.180 |
Why?
|
| Cancer Vaccines | 1 | 2021 | 47 | 0.180 |
Why?
|
| Cell Survival | 4 | 2006 | 573 | 0.180 |
Why?
|
| Vitiligo | 1 | 2023 | 126 | 0.180 |
Why?
|
| Endothelial Cells | 1 | 2022 | 184 | 0.180 |
Why?
|
| Cells | 1 | 2021 | 32 | 0.180 |
Why?
|
| Fibroblasts | 1 | 2022 | 392 | 0.170 |
Why?
|
| Muscular Diseases | 1 | 2020 | 50 | 0.170 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2021 | 116 | 0.170 |
Why?
|
| Antiviral Agents | 1 | 2023 | 321 | 0.170 |
Why?
|
| Interferon-gamma | 1 | 2022 | 567 | 0.160 |
Why?
|
| Synaptic Vesicles | 1 | 2019 | 25 | 0.160 |
Why?
|
| Thermodynamics | 4 | 2018 | 195 | 0.160 |
Why?
|
| Kinetics | 7 | 2005 | 764 | 0.160 |
Why?
|
| Receptors, LDL | 1 | 2019 | 34 | 0.160 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2019 | 17 | 0.150 |
Why?
|
| Lipoproteins, LDL | 1 | 2019 | 45 | 0.150 |
Why?
|
| Carbocyanines | 1 | 2019 | 29 | 0.150 |
Why?
|
| Myocardium | 1 | 2020 | 275 | 0.150 |
Why?
|
| Umbilical Cord | 1 | 2018 | 9 | 0.150 |
Why?
|
| Blood Proteins | 1 | 2019 | 76 | 0.150 |
Why?
|
| Chitosan | 1 | 2019 | 85 | 0.150 |
Why?
|
| Spheroids, Cellular | 1 | 2018 | 27 | 0.150 |
Why?
|
| Mannitol | 1 | 2018 | 14 | 0.150 |
Why?
|
| Propylene Glycols | 1 | 2018 | 9 | 0.150 |
Why?
|
| Neuropeptides | 1 | 2019 | 82 | 0.150 |
Why?
|
| Biomedical Research | 2 | 2024 | 263 | 0.150 |
Why?
|
| Heart Diseases | 1 | 2020 | 215 | 0.150 |
Why?
|
| Carotid Arteries | 1 | 2018 | 61 | 0.150 |
Why?
|
| Aptamers, Nucleotide | 1 | 2018 | 23 | 0.150 |
Why?
|
| RNA, Transfer | 2 | 2024 | 88 | 0.150 |
Why?
|
| Molecular Structure | 1 | 2019 | 384 | 0.140 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2018 | 168 | 0.140 |
Why?
|
| Peptide Nucleic Acids | 1 | 2017 | 16 | 0.140 |
Why?
|
| Organ Specificity | 1 | 2018 | 193 | 0.140 |
Why?
|
| Astrocytes | 1 | 2018 | 119 | 0.140 |
Why?
|
| Exoribonucleases | 1 | 2017 | 30 | 0.140 |
Why?
|
| Proteome | 1 | 2018 | 149 | 0.140 |
Why?
|
| Mice, Inbred Strains | 1 | 2017 | 189 | 0.140 |
Why?
|
| Fluorescent Dyes | 1 | 2019 | 198 | 0.140 |
Why?
|
| Acylation | 6 | 1999 | 16 | 0.140 |
Why?
|
| Triazoles | 1 | 2017 | 56 | 0.140 |
Why?
|
| Genetic Vectors | 3 | 2018 | 850 | 0.140 |
Why?
|
| Serine | 1 | 2017 | 91 | 0.130 |
Why?
|
| Drug Stability | 1 | 2017 | 143 | 0.130 |
Why?
|
| COS Cells | 1 | 2016 | 174 | 0.130 |
Why?
|
| Transferrin | 1 | 2016 | 70 | 0.130 |
Why?
|
| Cell Differentiation | 2 | 2019 | 1346 | 0.130 |
Why?
|
| Poly U | 2 | 1992 | 2 | 0.130 |
Why?
|
| Models, Molecular | 3 | 2017 | 1143 | 0.130 |
Why?
|
| Phosphorylation | 2 | 2017 | 937 | 0.130 |
Why?
|
| Biotechnology | 1 | 2016 | 44 | 0.120 |
Why?
|
| Muscle, Skeletal | 1 | 2020 | 733 | 0.120 |
Why?
|
| Small Molecule Libraries | 1 | 2015 | 58 | 0.120 |
Why?
|
| Microscopy, Fluorescence | 1 | 2016 | 400 | 0.120 |
Why?
|
| Forecasting | 1 | 2016 | 230 | 0.120 |
Why?
|
| DNA-Binding Proteins | 1 | 2021 | 1184 | 0.120 |
Why?
|
| Phenotype | 4 | 2021 | 1191 | 0.110 |
Why?
|
| Biomarkers, Tumor | 1 | 2018 | 502 | 0.110 |
Why?
|
| Peptides | 1 | 2018 | 573 | 0.110 |
Why?
|
| Internet | 2 | 2008 | 463 | 0.110 |
Why?
|
| Retinal Pigment Epithelium | 1 | 2013 | 35 | 0.100 |
Why?
|
| Anticodon | 1 | 1992 | 12 | 0.100 |
Why?
|
| Tyrosine-tRNA Ligase | 1 | 1992 | 2 | 0.100 |
Why?
|
| Reproducibility of Results | 2 | 2015 | 1638 | 0.100 |
Why?
|
| Mice, Obese | 2 | 2024 | 80 | 0.100 |
Why?
|
| Retina | 1 | 2013 | 124 | 0.100 |
Why?
|
| Oligodeoxyribonucleotides, Antisense | 2 | 2018 | 16 | 0.100 |
Why?
|
| RNA, Bacterial | 1 | 1992 | 73 | 0.100 |
Why?
|
| Saccharomyces cerevisiae | 3 | 1999 | 564 | 0.100 |
Why?
|
| Virus Replication | 2 | 2004 | 318 | 0.100 |
Why?
|
| Male | 5 | 2024 | 29469 | 0.090 |
Why?
|
| Escherichia coli | 2 | 1993 | 708 | 0.090 |
Why?
|
| Sequence Homology, Nucleic Acid | 2 | 2018 | 113 | 0.090 |
Why?
|
| Enzyme Inhibitors | 3 | 2007 | 373 | 0.080 |
Why?
|
| Magnesium | 3 | 2004 | 52 | 0.080 |
Why?
|
| HEK293 Cells | 2 | 2024 | 618 | 0.080 |
Why?
|
| Models, Genetic | 2 | 2008 | 260 | 0.080 |
Why?
|
| Substrate Specificity | 2 | 2005 | 337 | 0.080 |
Why?
|
| Catalysis | 3 | 2004 | 161 | 0.070 |
Why?
|
| Rabbits | 3 | 2013 | 332 | 0.070 |
Why?
|
| Genetic Complementation Test | 1 | 2008 | 63 | 0.070 |
Why?
|
| Nerve Tissue Proteins | 2 | 2022 | 422 | 0.070 |
Why?
|
| Time Factors | 5 | 2013 | 3740 | 0.070 |
Why?
|
| RNA, Antisense | 2 | 2007 | 51 | 0.070 |
Why?
|
| Microarray Analysis | 1 | 2008 | 63 | 0.070 |
Why?
|
| Plasmids | 3 | 2003 | 292 | 0.070 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2023 | 671 | 0.070 |
Why?
|
| Apoptosis | 4 | 2005 | 1066 | 0.070 |
Why?
|
| Genetic Testing | 1 | 2008 | 131 | 0.070 |
Why?
|
| Genes, BRCA1 | 1 | 2007 | 16 | 0.070 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2005 | 194 | 0.070 |
Why?
|
| RNA, Untranslated | 1 | 2007 | 102 | 0.070 |
Why?
|
| Cell Movement | 1 | 2008 | 445 | 0.060 |
Why?
|
| Numerical Analysis, Computer-Assisted | 1 | 2006 | 6 | 0.060 |
Why?
|
| Treatment Outcome | 1 | 2017 | 5584 | 0.060 |
Why?
|
| Silicon | 1 | 2006 | 18 | 0.060 |
Why?
|
| Epithelial Cells | 1 | 2008 | 389 | 0.060 |
Why?
|
| Prostatic Neoplasms | 2 | 2006 | 398 | 0.060 |
Why?
|
| RNA, Viral | 2 | 2004 | 272 | 0.060 |
Why?
|
| Manganese | 1 | 2005 | 24 | 0.060 |
Why?
|
| RNA, Transfer, Lys | 1 | 2004 | 1 | 0.060 |
Why?
|
| Ribonuclease III | 1 | 2005 | 88 | 0.060 |
Why?
|
| Transcription, Genetic | 2 | 2006 | 873 | 0.060 |
Why?
|
| Gentamicins | 1 | 2024 | 25 | 0.060 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2005 | 87 | 0.060 |
Why?
|
| Monocarboxylic Acid Transporters | 1 | 2024 | 12 | 0.060 |
Why?
|
| Diptera | 1 | 2004 | 4 | 0.060 |
Why?
|
| Peptidylprolyl Isomerase | 1 | 2004 | 20 | 0.060 |
Why?
|
| Collagen Type I | 1 | 2024 | 41 | 0.060 |
Why?
|
| Mixed Function Oxygenases | 1 | 2004 | 19 | 0.050 |
Why?
|
| Mice, Inbred mdx | 1 | 2023 | 15 | 0.050 |
Why?
|
| Congresses as Topic | 1 | 2024 | 75 | 0.050 |
Why?
|
| DNA Primers | 1 | 2004 | 292 | 0.050 |
Why?
|
| Signal Transduction | 3 | 2019 | 3019 | 0.050 |
Why?
|
| Janus Kinase 1 | 1 | 2023 | 11 | 0.050 |
Why?
|
| RNA, Plant | 1 | 2003 | 13 | 0.050 |
Why?
|
| Hepatic Stellate Cells | 1 | 2024 | 24 | 0.050 |
Why?
|
| Mice, Nude | 1 | 2024 | 271 | 0.050 |
Why?
|
| Proteins | 3 | 2004 | 749 | 0.050 |
Why?
|
| Computational Biology | 1 | 2006 | 352 | 0.050 |
Why?
|
| Luciferases | 1 | 2004 | 109 | 0.050 |
Why?
|
| Collagen | 1 | 2024 | 127 | 0.050 |
Why?
|
| Software | 1 | 2007 | 381 | 0.050 |
Why?
|
| Cystic Fibrosis | 1 | 2024 | 118 | 0.050 |
Why?
|
| ErbB Receptors | 1 | 2004 | 114 | 0.050 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2004 | 171 | 0.050 |
Why?
|
| RNA Precursors | 1 | 2003 | 76 | 0.050 |
Why?
|
| Amino Acid Motifs | 1 | 2003 | 151 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2006 | 1139 | 0.050 |
Why?
|
| Chemical Engineering | 1 | 2022 | 9 | 0.050 |
Why?
|
| Genetic Variation | 1 | 2005 | 370 | 0.050 |
Why?
|
| Antineoplastic Agents | 2 | 2005 | 660 | 0.050 |
Why?
|
| Amines | 2 | 1992 | 30 | 0.050 |
Why?
|
| Liver Cirrhosis | 1 | 2024 | 170 | 0.050 |
Why?
|
| HIV-1 | 2 | 2004 | 716 | 0.050 |
Why?
|
| Trachea | 1 | 2022 | 83 | 0.050 |
Why?
|
| Enzyme Activation | 3 | 2005 | 380 | 0.050 |
Why?
|
| Diacylglycerol O-Acyltransferase | 1 | 2021 | 12 | 0.050 |
Why?
|
| Protein Biosynthesis | 1 | 2024 | 317 | 0.050 |
Why?
|
| Autoimmunity | 1 | 2023 | 238 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2003 | 861 | 0.050 |
Why?
|
| Fibrosis | 1 | 2021 | 159 | 0.040 |
Why?
|
| Hepatitis C | 1 | 2003 | 151 | 0.040 |
Why?
|
| Dementia | 1 | 2024 | 258 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 2021 | 199 | 0.040 |
Why?
|
| Mice, Mutant Strains | 1 | 2021 | 302 | 0.040 |
Why?
|
| Protein Conformation | 1 | 2003 | 774 | 0.040 |
Why?
|
| Goals | 1 | 2021 | 91 | 0.040 |
Why?
|
| Drosophila | 1 | 2003 | 430 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2021 | 152 | 0.040 |
Why?
|
| Triglycerides | 1 | 2021 | 244 | 0.040 |
Why?
|
| Administration, Intranasal | 1 | 2019 | 28 | 0.040 |
Why?
|
| Binding Sites | 2 | 2017 | 900 | 0.040 |
Why?
|
| Aspartate-tRNA Ligase | 1 | 1999 | 1 | 0.040 |
Why?
|
| RNA, Transfer, Asp | 1 | 1999 | 1 | 0.040 |
Why?
|
| Skin Neoplasms | 1 | 2004 | 414 | 0.040 |
Why?
|
| Gene Knock-In Techniques | 1 | 2019 | 42 | 0.040 |
Why?
|
| Algorithms | 1 | 2005 | 1003 | 0.040 |
Why?
|
| Extracorporeal Circulation | 1 | 2019 | 5 | 0.040 |
Why?
|
| Protein Binding | 1 | 2003 | 1601 | 0.040 |
Why?
|
| Solid-Phase Synthesis Techniques | 1 | 2018 | 3 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 520 | 0.040 |
Why?
|
| Models, Biological | 1 | 2003 | 1180 | 0.040 |
Why?
|
| Dendritic Cells | 1 | 2021 | 523 | 0.040 |
Why?
|
| Microfilament Proteins | 1 | 2019 | 111 | 0.040 |
Why?
|
| Macromolecular Substances | 1 | 2018 | 160 | 0.040 |
Why?
|
| Genetic Loci | 1 | 2018 | 118 | 0.040 |
Why?
|
| Molecular Conformation | 1 | 2017 | 133 | 0.030 |
Why?
|
| Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2018 | 97 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2006 | 1193 | 0.030 |
Why?
|
| Caenorhabditis elegans | 1 | 2003 | 675 | 0.030 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2018 | 336 | 0.030 |
Why?
|
| Cell Membrane | 1 | 2018 | 493 | 0.030 |
Why?
|
| Inflammation | 1 | 2021 | 1138 | 0.030 |
Why?
|
| Caspases | 2 | 2005 | 172 | 0.030 |
Why?
|
| Cytoplasm | 2 | 2005 | 277 | 0.030 |
Why?
|
| Genome, Viral | 2 | 2004 | 133 | 0.030 |
Why?
|
| Intravitreal Injections | 1 | 2013 | 49 | 0.030 |
Why?
|
| Obesity | 1 | 2021 | 1230 | 0.030 |
Why?
|
| Eye Diseases | 1 | 2013 | 35 | 0.030 |
Why?
|
| Inorganic Pyrophosphatase | 1 | 1993 | 1 | 0.030 |
Why?
|
| Pyrophosphatases | 1 | 1993 | 11 | 0.030 |
Why?
|
| Down-Regulation | 2 | 2004 | 318 | 0.030 |
Why?
|
| Yeasts | 1 | 1992 | 51 | 0.020 |
Why?
|
| Cattle | 1 | 1992 | 308 | 0.020 |
Why?
|
| Mitochondria | 2 | 2005 | 366 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2021 | 5403 | 0.020 |
Why?
|
| Young Adult | 1 | 2021 | 4630 | 0.020 |
Why?
|
| Adolescent | 1 | 2021 | 6165 | 0.020 |
Why?
|
| Integrin beta1 | 1 | 2008 | 32 | 0.020 |
Why?
|
| beta Catenin | 1 | 2008 | 93 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 2008 | 89 | 0.020 |
Why?
|
| United States | 1 | 2021 | 7721 | 0.020 |
Why?
|
| Wound Healing | 1 | 2008 | 189 | 0.020 |
Why?
|
| Genetic Techniques | 1 | 2007 | 39 | 0.020 |
Why?
|
| Actins | 1 | 2008 | 259 | 0.020 |
Why?
|
| Aged | 1 | 2021 | 14249 | 0.010 |
Why?
|
| BH3 Interacting Domain Death Agonist Protein | 1 | 2005 | 9 | 0.010 |
Why?
|
| Framycetin | 1 | 2005 | 1 | 0.010 |
Why?
|
| Caspase Inhibitors | 1 | 2005 | 21 | 0.010 |
Why?
|
| Cytochromes c | 1 | 2005 | 29 | 0.010 |
Why?
|
| Thapsigargin | 1 | 2004 | 17 | 0.010 |
Why?
|
| Electron Spin Resonance Spectroscopy | 1 | 2005 | 26 | 0.010 |
Why?
|
| Magnesium Chloride | 1 | 2004 | 6 | 0.010 |
Why?
|
| Cations, Divalent | 1 | 2004 | 23 | 0.010 |
Why?
|
| Taxoids | 1 | 2004 | 26 | 0.010 |
Why?
|
| Schistosoma | 1 | 2004 | 3 | 0.010 |
Why?
|
| Ribonuclease H | 1 | 2004 | 18 | 0.010 |
Why?
|
| Deoxycytidine | 1 | 2004 | 42 | 0.010 |
Why?
|
| Membrane Potentials | 1 | 2005 | 141 | 0.010 |
Why?
|
| Caspase 3 | 1 | 2005 | 109 | 0.010 |
Why?
|
| Catalase | 1 | 2004 | 24 | 0.010 |
Why?
|
| Protein Kinase C-alpha | 1 | 2004 | 16 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 544 | 0.010 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2004 | 39 | 0.010 |
Why?
|
| Vitamin K Epoxide Reductases | 1 | 2004 | 3 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2008 | 981 | 0.010 |
Why?
|
| Cisplatin | 1 | 2004 | 139 | 0.010 |
Why?
|
| Hot Temperature | 1 | 2004 | 130 | 0.010 |
Why?
|
| Adult | 1 | 2021 | 16620 | 0.010 |
Why?
|
| Clathrin | 1 | 2004 | 23 | 0.010 |
Why?
|
| Spodoptera | 1 | 2004 | 28 | 0.010 |
Why?
|
| Middle Aged | 1 | 2021 | 17358 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2004 | 25 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2004 | 487 | 0.010 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2004 | 78 | 0.010 |
Why?
|
| Protein Kinase C | 1 | 2004 | 103 | 0.010 |
Why?
|
| DNA, Viral | 1 | 2004 | 231 | 0.010 |
Why?
|
| Drug Resistance | 1 | 2004 | 112 | 0.010 |
Why?
|
| Warfarin | 1 | 2004 | 109 | 0.010 |
Why?
|
| Electroporation | 1 | 2003 | 35 | 0.010 |
Why?
|
| Reactive Oxygen Species | 1 | 2004 | 224 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2004 | 455 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2003 | 149 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2004 | 291 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2003 | 182 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2004 | 202 | 0.010 |
Why?
|
| Cell Division | 1 | 2004 | 450 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2005 | 452 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2004 | 515 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2004 | 669 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2004 | 324 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2004 | 392 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2003 | 610 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2005 | 705 | 0.010 |
Why?
|
| Molecular Mimicry | 1 | 1999 | 32 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 1999 | 247 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1999 | 383 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2003 | 866 | 0.010 |
Why?
|